HAEMACCEL INJECTION 500 ML

Haemaccel Injection 500ml is a plasma volume expander used to replace blood volume lost due to surgery, accident, or burns.

The active ingredient in Haemaccel Injection 500ml is Polygeline.

Haemaccel Injection 500ml is used to treat hypovolemia (decreased blood volume), which can be caused by hemorrhage, dehydration, or other medical conditions.

Haemaccel Injection 500ml is administered intravenously (IV) by a healthcare professional.

Common side effects of Haemaccel Injection 500ml may include nausea, vomiting, chills, and fever.

Limited data is available on the use of Haemaccel Injection 500ml during pregnancy. It should only be used if clearly needed and under medical supervision.

Haemaccel Injection 500ml should be stored at room temperature, away from direct sunlight and heat.

Overdosing on Haemaccel Injection 500ml can lead to an increase in blood volume, which may cause symptoms such as high blood pressure, difficulty breathing, and heart failure. Seek immediate medical attention if you suspect an overdose.

Haemaccel Injection 500ml can interact with other medications, especially those that affect blood clotting or increase blood pressure. It is important to inform your doctor about all medications you are taking.

Haemaccel Injection 500ml is contraindicated in individuals with a known allergy to Polygeline or any component of the product, as well as in people with severe heart failure or pulmonary edema.

Haemaccel Injection 500ml can be used in children, but the dosage should be adjusted based on the child's weight and clinical condition.

Haemaccel Injection 500ml is available under the brand name Haemaccel.

There are no known long-term risks associated with the use of Haemaccel Injection 500ml when used as directed.

No, Haemaccel Injection 500ml should only be administered by a healthcare professional.

If you experience symptoms of an allergic reaction after receiving Haemaccel Injection 500ml, such as hives, difficulty breathing, or swelling of the face or throat, seek immediate medical attention.

Haemaccel is used as a plasma volume expander to treat or prevent low blood volume (hypovolemia) and shock, typically due to blood or plasma loss from trauma, surgery, burns, or severe dehydration. It helps restore and maintain adequate blood pressure and organ perfusion until the underlying cause is addressed and, when necessary, blood products are given.

Haemaccel contains polygeline, a colloid that remains mainly within the blood vessels and exerts an oncotic (osmotic) effect. This draws fluid into the circulation and expands plasma volume, which helps increase blood pressure and improve blood flow to vital organs. It does not replace red blood cells or clotting factors, so it is not a substitute for blood transfusion when those are specifically needed.

In patients with normal liver function, Haemaccel is generally considered safe when used under medical supervision. However, in people with significant liver disease, fluid balance, protein metabolism, and coagulation can be altered, so the use of any volume expander, including Haemaccel, requires caution. The doctor will carefully monitor liver function tests, fluid status, and coagulation parameters and may adjust treatment or choose alternative fluids if there is a risk of worsening liver-related complications.

Yes, kidney function is an important consideration when using Haemaccel. Adequate plasma volume can help support kidney perfusion and function, but excessive or inappropriate use may contribute to fluid overload, which can strain the kidneys, especially in patients with pre-existing kidney impairment. In moderate to severe renal dysfunction, Haemaccel should be used with great caution or may be avoided, and kidney function, urine output, and electrolyte levels must be closely monitored during therapy.

Use of Haemaccel during pregnancy should be based on a careful assessment of risks and benefits by the treating physician. Data in pregnant women are limited, so it is generally reserved for situations where restoring blood volume is clearly necessary for the health of the mother and fetus, such as in significant blood or fluid loss. The lowest effective amount is used, and the mother and fetus are monitored closely. It should not be used routinely in pregnancy without a clear medical indication.

Information on the excretion of polygeline into breast milk is limited. Because Haemaccel is given in acute or hospital settings and is largely confined to the intravascular space and then eliminated, it is not expected to pose a major risk to a breastfed infant when used appropriately. However, the decision to use Haemaccel in a breastfeeding woman should be made by the physician, who will weigh the clinical need for volume expansion against any theoretical risks and may advise monitoring the infant for any unusual symptoms.

Haemaccel itself is not known to directly impair the ability to drive or operate machinery. However, the conditions for which it is given—such as shock, major blood loss, or serious illness—as well as associated medications (for example, sedatives, painkillers, or anesthetics) can significantly affect alertness, blood pressure, and coordination. You should not drive or operate machinery until your doctor confirms that your overall condition is stable and it is safe for you to do so.

There is no specific documented interaction between Haemaccel and alcohol, but alcohol can affect blood pressure, hydration status, liver function, and recovery from illness or surgery. Because Haemaccel is usually given in acute or serious clinical situations, alcohol consumption is generally discouraged during the recovery period. Follow your doctor’s advice, and avoid alcohol until you are fully stable and have been medically cleared to resume normal activities, including drinking alcohol if appropriate.

Haemaccel can cause allergic or anaphylactoid reactions in some patients. Symptoms may include skin rash, itching, flushing, hives, swelling of the face or throat, difficulty breathing, wheezing, chest tightness, rapid or weak pulse, low blood pressure, nausea, or vomiting. Severe reactions can progress to anaphylactic shock, which is life-threatening. For this reason, Haemaccel is administered under close medical supervision, usually with monitoring of vital signs, and emergency treatment must be available. If any signs of allergy appear, the infusion is stopped immediately and appropriate therapy is given.

Haemaccel is generally contraindicated in patients with known hypersensitivity to polygeline or any component of the solution, in those with severe fluid overload states such as marked heart failure or pulmonary edema, and in certain severe kidney disorders where fluid excretion is markedly impaired. It should also be avoided or used with extreme caution in patients with severe electrolyte imbalances, uncontrolled bleeding disorders, or conditions where additional volume expansion could be dangerous. The treating physician will evaluate your medical history, current condition, and laboratory results before deciding whether Haemaccel is appropriate.

No, Haemaccel does not replace the need for a blood transfusion when there is significant anemia or loss of red blood cells. It expands plasma volume and helps stabilize blood pressure, but it does not provide red blood cells, platelets, or clotting factors. In cases of major blood loss, Haemaccel may be used as part of initial resuscitation, but blood and blood components may still be required to restore oxygen-carrying capacity and correct coagulation abnormalities, as determined by the treating physician.